Lars Fruergaard Jørgensen, Novo Nordisk CEO (Photographer: Christopher Goodney/Bloomberg via Getty Images)
August 7, 2024 07:13 AM EDT
Pharma
Manufacturing

No­vo Nordisk dou­bles US We­govy pre­scrip­tions as short­ages start to ease, but earn­ings fall be­low ex­pec­ta­tions 

Anna Brown

News Reporter

Near­ly all of No­vo Nordisk’s block­buster GLP-1 We­govy and Ozem­pic drugs have been tak­en off the FDA short­age list as the com­pa­ny re­ports a dou­bling …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

Ex-Kite lead­ers step in at Kyver­na as CEO ex­its af­ter land­ing year's sec­ond-biggest IPO

BioN­Tech rolls out Phase 2 lung can­cer da­ta as VEGF bis­pecifics take cen­ter stage

Im­mat­ics los­es Bris­tol My­er­s' sup­port on Phase 1 bis­pe­cif­ic T cell en­gager

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times